Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Christiane J. Bruns

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6590-8181; OpenAlex author ID A5048356727, A5147293863. Sources: OpenAlex.

Their work

Papers
53 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
3
Collaborators
158
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 5 papers · 2016: 2 papers · 2017: 3 papers · 2018: 5 papers · 2019: 4 papers · 2020: 5 papers · 2021: 5 papers · 2022: 3 papers · 2023: 7 papers · 2024: 4 papers · 2025: 2 papers · 2026: 3 papers

Papers 50 of 53

  1. LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. Co-author DOI 10.1038/s41419-026-09075-4↗
  2. Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies. Co-author DOI 10.1038/s41420-026-02948-9↗
  3. MTAP-Deficiency Identifies a Myofibroblastic and Immune-Attenuated Tumor Microenvironment Subtype in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10656530/v1↗
  4. Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Co-author DOI 10.1007/s13402-025-01128-8↗
  5. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  6. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  7. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  8. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Co-author DOI 10.1016/j.tranon.2024.102044↗
  9. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02488-4↗
  10. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Co-author DOI 10.1007/s00432-022-04518-9↗
  11. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  12. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  13. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  14. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.medj.2023.07.010↗
  15. Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072049↗
  16. Therapy of Locally Advanced and Oligometastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers15245881↗
  17. [Surgical treatment of pancreatic cancer-What is new?] Last author DOI 10.1007/s00104-022-01618-7↗
  18. [Synopsis-S3 guidelines pancreatic cancer]. Co-author DOI 10.1007/s00104-022-01637-4↗
  19. Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. Co-author DOI 10.1007/s00411-022-00962-w↗
  20. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Co-author DOI 10.1007/s13402-020-00559-9↗
  21. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Co-author DOI 10.1038/s41392-021-00659-4↗
  22. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  23. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13112689↗
  24. IL-17B/RB Activation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Metabolism and Growth. Co-author DOI 10.3390/cancers13215338↗
  25. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer]. Last author DOI 10.1007/s00104-020-01172-0↗
  26. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Co-author DOI 10.1038/s41392-020-0146-6↗
  27. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  28. The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer. Co-author DOI 10.3390/ijms21062215↗
  29. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Last author DOI 10.7150/thno.43093↗
  30. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". Co-author DOI 10.1186/s12885-019-6448-9↗
  31. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2019.01160↗
  32. Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Co-author DOI 10.3390/cancers11060874↗
  33. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.32899↗
  34. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. Last author DOI 10.1007/s00104-018-0626-1↗
  35. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-018-2717-2↗
  36. Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo. Co-author DOI 10.1161/atvbaha.117.310262↗
  37. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. Last author DOI 10.1186/s12885-018-4973-6↗
  38. First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report. Co-author DOI 10.1186/s12885-018-5151-6↗
  39. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-017-2351-4↗
  40. Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Co-author DOI 10.1155/2017/6012810↗
  41. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pan… Last author DOI 10.1186/s12885-017-3186-8↗
  42. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  43. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. Last author DOI 10.3892/ijo.2016.3512↗
  44. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospe… Co-author DOI 10.1007/s00066-014-0737-7↗
  45. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Last author DOI 10.1007/s11523-014-0323-z↗
  46. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pa… Co-author DOI 10.1007/s11523-015-0360-2↗
  47. Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.362↗
  48. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular "pseudoinflammation" contributing to an aggressiv… Last author DOI 10.18632/oncotarget.2494↗
  49. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a… Last author DOI 10.1097/cad.0000000000000146↗
  50. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analys… Co-author DOI 10.1007/s00432-012-1371-3↗

Closest collaborators

The 25 strongest of 158 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yue Zhao · 26 shared papers, 2015–2026 · strength 2.88
  2. Felix Popp · 17 shared papers, 2017–2026 · strength 2.36
  3. Alexander Quaas · 11 shared papers, 2018–2026 · strength 1.83
  4. Alexander Ioannis Damanakis · 9 shared papers, 2018–2024 · strength 1.46
  5. Qiongzhu Dong · 8 shared papers, 2019–2026 · strength 1.15
  6. Hendrik Seeliger · 9 shared papers, 2012–2025 · strength 0.98
  7. Zhefang Wang · 6 shared papers, 2019–2026 · strength 0.97
  8. Su Ir Lyu · 5 shared papers, 2023–2026 · strength 0.97
  9. Karl Knipper · 5 shared papers, 2023–2026 · strength 0.97
  10. Thomas Schmidt · 5 shared papers, 2022–2024 · strength 0.94
  11. Ioannis Pozios · 7 shared papers, 2017–2025 · strength 0.92
  12. Peter Čamaj · 7 shared papers, 2015–2025 · strength 0.61
  13. Jens Werner · 5 shared papers, 2016–2025 · strength 0.56
  14. Nina A. Hering · 3 shared papers, 2021–2025 · strength 0.54
  15. Stefan Hubert Boeck · 7 shared papers, 2011–2025 · strength 0.53
  16. Jiahui Li · 5 shared papers, 2019–2021 · strength 0.52
  17. Lucas D. Lee · 3 shared papers, 2021–2025 · strength 0.51
  18. Jiangang Zhao · 4 shared papers, 2017–2026 · strength 0.50
  19. Waldemar H. Uhl · 3 shared papers, 2022–2024 · strength 0.48
  20. Werner Hartwig · 4 shared papers, 2016–2024 · strength 0.47
  21. Thomas Knösel · 5 shared papers, 2015–2023 · strength 0.46
  22. Hana Algül · 3 shared papers, 2018–2026 · strength 0.43
  23. Florian Gebauer · 3 shared papers, 2018–2020 · strength 0.42
  24. Philipp Lohneis · 3 shared papers, 2020–2025 · strength 0.42
  25. Feng Yang · 4 shared papers, 2019–2023 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.